In 2022, the global anti-viral drugs market is expected to be worth $59,596.8 million. The introduction of generic antiviral medicines, as well as increased awareness about the availability of various vaccines for viral infections, are affecting growth throughout the forecast period. Between 2022 and 2032, the overall demand for Anti-Viral Drugs is expected to grow at a CAGR of 3.9%, reaching around US$ 87,675.36 Million.

Anti-viral drugs are medications that are specifically used to treat viral infections. Most anti-viral drugs, like antibiotics, are used to treat specific viral infections, whereas a broad-spectrum anti-viral drug is effective against a wide range of viruses. Antiviral drugs do not kill their target pathogens; instead, they inhibit their growth.

The global anti-viral drugs market is expected to grow at a moderate rate in the pharmaceutical market due to increased awareness, an increase in diseased population, and the introduction of new drugs with improved efficacy.

Several major patents, including Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine, will expire during the forecast period. The patent expirations of these blockbuster drugs are expected to spark generic competition in the antivirals therapeutics market, making it more competitive.

Late-stage pipeline drugs are expected to enter the market, positively affecting the market. Most antivirals are considered relatively harmless to the host and are thus used to treat infections. They differ from viricides, which are not medications but can destroy or deactivate virus particles both outside and inside the body.

Anti-viral drugs are used to treat patients with herpes viruses, HIV, influenza A and B viruses, and hepatitis B and C viruses.

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Browse More@

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

  • Hepatitis-C antivirals
  • HIV antivirals
  • Herpes antivirals
  • Hepatitis-B antivirals
  • Influenza antivirals
  • Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers